News Article

Leading cancer care provider GenesisCare UK has secured refinancing of up to £140 million, provided by Pemberton Asset Management, a leading private credit manager in Europe, and Barclays.

GenesisCare UK is the UK’s leading independent specialist cancer care provider and currently operates 14 specialist outpatient centres. It is driven by transforming cancer care with advanced diagnostics, medical oncology, radiotherapy, and theranostics.

Candesic is proud to have provided vendor due diligence to GenesisCare UK with a team led by Senior Partner Dr Michelle Tempest and Senior Engagement Manager Jack Zeng.

Justin Hely, GenesisCare’s CEO in the UK and Europe, said: “We are delighted to have completed our refinancing, which reinforces the confidence we and our partners have in the GenesisCare business and our growth strategy.  Our focus remains on expanding our network of world-class cancer care centres and delivering the highest possible standards of care to patients with a suspected or confirmed cancer diagnosis.”

Richard Meehan, Managing Director – Origination, at Pemberton: “We are delighted to be partnering with GenesisCare UK, who are at the forefront of cancer treatment in the UK. The Group’s use of advanced treatment methods and well-invested facilities enable their clinicians to deliver the highest standard of care for patients. We look forward to supporting Justin and his team in realising their growth aspirations over the coming years”

Steve Fergus, Head of Healthcare at Barclays Corporate Banking, said: “We are pleased to be supporting the team at GenesisCare UK with this refinancing, and look forward to helping enable their continued success in the years ahead. This new relationship further underlines our ongoing commitment to invest for growth within this important sector.”